Next-Gen Oncology: Trials, Targets, and Approvals
Kilder
- Biospace: Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals - BioSpace
- biospace.com: Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals - BioSpace
- Bioworld: FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
- bioworld.com: FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
- Statnews: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment - statnews.com
- statnews.com: CMS proposes rolling back breakthrough device payment flexibilities | STAT - statnews.com
- Fiercebiotech: Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial - Fierce Biotech
- fiercebiotech.com: Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial - Fierce Biotech
- Nature: Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial - Nature
- biopharmadive.com: FDA moves toward easing restrictions on certain peptides - BioPharma Dive
- biospace.com: FDA mulls compounding for peptides previously flagged over safety risks - BioSpace
- wikimedia: Photo by The U.S. Food and Drug Administration / Wikimedia Commons / Public domain
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.